What Cancers Cause Elevated Ferritin Levels?

Elevated ferritin levels show up across a wide range of cancers, from blood malignancies like acute myeloid leukemia and lymphoma to solid tumors of the liver, kidney, lung, and pancreas. The connection between cancer and high ferritin is not a coincidence or a side effect of treatment alone. Tumors actively disrupt iron metabolism, and in many cases ferritin rises in proportion to how aggressive or advanced the disease is. But ferritin is far from a clean diagnostic signal, and understanding what it means in context matters more than the number itself.

Blood Cancers and Ferritin

The strongest and most clinically recognized link between elevated ferritin and cancer is in hematologic malignancies. Acute myeloid leukemia stands out in particular. AML is an aggressive cancer of the bone marrow, and patients frequently present with increased ferritin at diagnosis. Those elevated levels are tied to worse long-term survival, making ferritin both a byproduct of the disease and a prognostic signal.¹ The problem compounds during treatment: intensive chemotherapy and repeated blood transfusions load patients with iron, driving ferritin even higher. In one study tracking leukemia patients over six months of treatment, about 88% of the AML group had ferritin above 1,000 ng/mL, compared to a much smaller proportion in the acute lymphoblastic leukemia group.² Certain AML subtypes, particularly the myelomonocytic and monocytic forms, tend to have especially high ferritin, and higher iron expression in those patients correlates with shortened survival.³

Hodgkin lymphoma, particularly in pediatric patients, also shows a clear ferritin connection. Ferritin levels at baseline correlate with disease activity, and they drop to lower values in patients who achieve remission. Researchers have suggested that grouping patients by ferritin levels could serve as a useful outcome predictor, even when transfusion-related iron loading is not a major factor.⁴ The pattern of ferritin tracking disease activity and falling during remission is one of the more consistent findings across hematologic cancers, and it reinforces the idea that the tumor itself drives at least part of the elevation.

Solid Tumors That Raise Ferritin

The relationship between ferritin and solid tumors is less tidy than the blood cancer story but still meaningful. Several organ-specific cancers have been studied individually, with varying degrees of evidence linking them to elevated ferritin.

Kidney Cancer

Renal cell carcinoma has some of the older and more convincing data. In a study comparing patients with kidney cancer to healthy controls, the average ferritin in patients was roughly four times higher. Ferritin levels climbed steadily with advancing stage, and they dropped after surgical removal of the kidney in early-stage disease. The tumor tissue itself contained dramatically more ferritin than normal kidney tissue, pointing to the cancer as the source.⁵ This stage-dependent pattern, where ferritin rises with disease burden and falls after treatment, is one of the hallmarks of a biologically meaningful biomarker rather than a coincidental finding.

Lung Cancer

Lung cancer has a more mixed picture. Ferritin levels correlate with tumor size in some studies, particularly in male patients.⁶ In small-cell lung cancer patients receiving immunotherapy, lower baseline ferritin predicted a better response to treatment. Patients with lower pre-treatment ferritin had longer progression-free survival, with a median of about seven months compared to four months in the high-ferritin group.⁷ Tracking how ferritin changes during treatment may carry even more information than the baseline level alone.

Liver Cancer

Hepatocellular carcinoma, the most common type of liver cancer, complicates the ferritin picture because the liver is the body’s primary iron storage organ. You would expect ferritin to be disturbed in liver cancer, and it is: roughly 41% of patients in one study of non-viral liver disease-related liver cancer had elevated ferritin.⁸ But when researchers tested whether pre-treatment ferritin could independently predict survival in patients undergoing a common treatment procedure, it could not. Other tumor-related factors outperformed it.⁹ So while liver cancer raises ferritin, the signal is muddied by the organ’s normal role in iron metabolism and by confounders like alcohol use and diabetes.

Pancreatic Cancer

Pancreatic ductal adenocarcinoma, one of the deadliest solid tumors, has also been linked to higher ferritin levels. Research has found that elevated ferritin correlates with a poorer prognosis in this cancer, and scientists are actively investigating how ferritin interacts with the metabolic machinery that drives KRAS-mutant pancreatic cancer cell growth.¹⁰ The ferritin elevation here appears to be more than a bystander effect; the iron-storage protein may actively fuel tumor metabolism.

Gynecological Cancers

In a study of women with gynecological cancers, patients with high ferritin (above 150 μg/L) had significantly shorter survival times than those with normal or low levels. The risk of death was roughly 2.7 times higher in the high-ferritin group on initial analysis, though when other prognostic factors were accounted for simultaneously, ferritin lost its independent predictive power.¹¹ This pattern, where ferritin is associated with worse outcomes in simple analyses but loses independence in more rigorous models, shows up repeatedly across cancer types and is part of why the field remains cautious about using ferritin as a standalone marker.

Neuroblastoma in Children

Neuroblastoma deserves special mention because ferritin has been used as a prognostic factor in this childhood cancer for decades. Children with advanced-stage neuroblastoma who present with elevated ferritin have a significantly poorer prognosis, and this relationship holds independent of disease stage and age at diagnosis.¹² The International Neuroblastoma Risk Group confirmed this with a large dataset: five-year event-free survival ranged from about 87% in children with very low ferritin down to roughly 48% in those with ferritin at or above 90 ng/mL. Even within the high-risk group treated with modern therapies, ferritin maintained independent prognostic ability alongside other established risk factors.¹³

Importantly, the tumor itself appears to be the source of the ferritin. Ferritin levels return to normal when children achieve remission, and laboratory work with binding assays supports the conclusion that neuroblastoma cells produce and secrete the excess ferritin directly.¹⁴ Among all cancer types, neuroblastoma provides perhaps the clearest evidence that ferritin elevation is not just collateral damage from inflammation or treatment but a product of the malignancy itself.

Ferritin and Prognosis Across Cancer Types

A recent systematic review and meta-analysis pooling data from multiple cancer types found that elevated circulating ferritin was associated with roughly a 78% increased risk of death from any cause in adult cancer patients.¹⁵ That is a substantial effect size and consistent enough across different cancers to suggest that high ferritin is not merely a quirk of one tumor type. Whether the mechanism is the same across all of them is another question, but the prognostic signal is real and broad.

In CAR T-cell therapy for blood cancers, ferritin carries a different but related prognostic signal. Higher ferritin levels before treatment are associated with worse progression-free and overall survival, roughly doubling to tripling the hazard of poor outcomes.¹⁶ And after CAR T-cell infusion, extreme ferritin spikes above 10,000 ng/mL are a strong signal of severe cytokine release syndrome, one of the most dangerous complications of this treatment.

Is Ferritin a Reliable Way to Screen for Cancer?

The short answer is no, not on its own. While many cancers raise ferritin, so do a long list of non-cancerous conditions: liver disease, chronic infections, autoimmune disorders, hemochromatosis, metabolic syndrome, heavy alcohol consumption, and simple acute inflammation from something as common as a respiratory infection. A systematic review examining ferritin’s potential as a cancer biomarker characterized the evidence as inconsistent.¹⁷ Ferritin is far too nonspecific to work as a screening tool in the general population. A high reading could mean iron overload, inflammation, liver damage, or cancer, and without additional context, there is no way to tell which.

This is worth emphasizing because people sometimes receive elevated ferritin results on routine bloodwork and worry about cancer. In the vast majority of cases, the cause is something else entirely. Even genetic conditions can produce very high ferritin levels without any disease at all. Hereditary hyperferritinemia can arise from mutations affecting ferritin regulation, and the resulting ferritin elevations may have nothing to do with iron overload or malignancy.¹⁸ If your doctor finds an unexplained ferritin elevation, the workup typically involves ruling out these far more common explanations before anyone starts thinking about cancer.

When a Sudden Ferritin Spike Signals Trouble

There is one scenario where an abrupt ferritin rise does carry a more ominous signal. In patients with thalassemia who are already being monitored regularly, researchers found that ferritin levels were stable in the years leading up to a cancer diagnosis but then surged sharply in the zero-to-six-month window before cancer was detected. The average increase was about 129% above baseline during that period. Critically, other markers of iron overload, including liver iron content and cardiac iron measurements, stayed flat at the same time.¹⁹ In other words, the ferritin jump was not reflecting more iron in the body. It was reflecting a new malignant process. For patients already under close monitoring for iron overload, a sudden, unexplained ferritin spike that diverges from other iron markers deserves prompt investigation for malignancy.

A Laboratory Trap Worth Knowing About

There is a counterintuitive testing pitfall that can mislead clinicians in the opposite direction. When ferritin levels are extremely high, certain types of laboratory assays can actually report falsely low numbers. This is called the hook effect: the analyte overwhelms the test’s antibodies, and the measurement curves back down instead of climbing higher. Depending on the assay platform, this can happen at ferritin concentrations above 40,000 μg/L or higher.²⁰ In patients undergoing CAR T-cell therapy or experiencing hemophagocytic syndromes, ferritin can spike into the tens of thousands, exactly the range where the hook effect is most dangerous. A result that looks only mildly elevated may actually represent a dramatically high ferritin that the assay could not handle. Labs can catch this by diluting the sample and retesting, but clinicians have to think to ask for it.²¹

Iron Chelation and Ferroptosis as Emerging Treatment Angles

If excess iron feeds cancer, the logical question is whether removing that iron could help. Iron chelation therapy, long used to manage iron overload in conditions like thalassemia and sickle cell disease, is being investigated for anticancer potential. Chelating drugs like deferiprone have shown the ability to remove excess iron from renal cancer cells in laboratory studies and may inhibit metastasis. Early work has also explored chelation in prostate cancer and breast cancer, where the mechanism involves disrupting cancer stem cells rather than simply lowering iron levels.²²

A parallel and increasingly active line of research targets ferroptosis, a form of cell death driven by iron-dependent lipid damage. Cancer cells that hoard iron may be particularly vulnerable to having that iron weaponized against them through ferroptosis-inducing drugs. Multiple clinical trials are exploring this strategy across different cancer types. Iron chelation and ferroptosis targeting are not yet standard cancer treatments, but they represent a shift in thinking: rather than viewing ferritin elevation as merely a prognostic signal to observe, researchers are asking whether the underlying iron dysregulation can be turned into a therapeutic target. Colorectal cancer is another area where iron chelation’s mechanisms and therapeutic potential are being systematically reviewed.²³

Ferritin Elevation in Veterinary Oncology

The ferritin-cancer connection is not unique to humans. In dogs, malignant liver tumors produce significantly higher ferritin levels than benign ones. One study found that about 89% of dogs with malignant liver tumors had elevated ferritin, compared to 60% with benign tumors and 17% of healthy controls.²⁴ Hemangiosarcoma, an aggressive cancer of blood vessel walls that commonly affects the spleen in dogs, tells a similar story: all dogs with splenic hemangiosarcoma in one study had ferritin above the normal limit, with some cases of hematoma and lymphoma also showing elevations.²⁵ The cross-species consistency of this pattern strengthens the case that the relationship between iron metabolism and cancer is biologically deep rather than incidental. It also means veterinarians face the same interpretive challenge as physicians: elevated ferritin in a dog is a red flag, but not proof of malignancy on its own.